Results 261 to 270 of about 44,151 (306)
Arrestin recognizes GPCRs independently of the receptor state
Petrovic I +8 more
europepmc +1 more source
Hepatotoxicity Associated with Carvedilol [PDF]
Annals of Pharmacotherapy, 2001 OBJECTIVE: To report a severe episode of pruritus and elevated serum transaminases in a patient who was receiving carvedilol. CASE SUMMARY: A 40-year-old white man who had been taking carvedilol for the treatment of cardiomyopathy presented to the emergency department with pruritus over his entire body.
Jenny Stein, Kathleen O Hagmeyer
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The pharmacology of carvedilol
European Journal of Clinical Pharmacology, 1990Carvedilol is a potent antihypertensive agent with a dual mechanism of action. At relatively low concentrations it is a competitive beta-adrenoceptor antagonist and a vasodilator, whereas at higher concentrations it is also a calcium channel antagonist.
Nichols Aj +4 more
openaire +2 more sources
AAPS PharmSciTech, 2021
Carvedilol is administered as a racemic mixture for the therapy of hypertension and heart failure. S-enantiomer is the dominant conformation of pharmacodynamics, but its further development was obstructed by its poor bioavailability.
Qi Zhang +5 more
semanticscholar +1 more source
Carvedilol is administered as a racemic mixture for the therapy of hypertension and heart failure. S-enantiomer is the dominant conformation of pharmacodynamics, but its further development was obstructed by its poor bioavailability.
Qi Zhang +5 more
semanticscholar +1 more source
The American Journal of Cardiology, 2004
Carvedilol is a third-generation, neurohormonal antagonist with multiple activities. It blocks both beta(1)- and beta(2)-adrenergic receptors, enhances vasodilation via alpha(1)-adrenergic blockade, and, at high concentrations, has ion channel-blocking activities. Carvedilol lacks sympathomimetic activity.
Brian Dulin, William T. Abraham
openaire +3 more sources
Carvedilol is a third-generation, neurohormonal antagonist with multiple activities. It blocks both beta(1)- and beta(2)-adrenergic receptors, enhances vasodilation via alpha(1)-adrenergic blockade, and, at high concentrations, has ion channel-blocking activities. Carvedilol lacks sympathomimetic activity.
Brian Dulin, William T. Abraham
openaire +3 more sources
Carvedilol for Systemic Hypertension
Journal of Cardiovascular Pharmacology, 1987Twenty-four-hour profiles of intraarterial ambulatory blood pressure (BP) and heart rate were significantly reduced by administration of carvedilol, a new beta-blocking drug with vasodilating properties. Twelve patients were given carvedilol, 25 mg twice daily for 2 weeks; the dose was then increased to 50 mg twice daily if the target BP was not ...
Avijit Lahiri +4 more
openaire +5 more sources
Electrophysiologic Effects of Carvedilol: Is Carvedilol an Antiarrhythmic Agent?
Pacing and Clinical Electrophysiology, 2005The cardiovascular drug carvedilol is characterized by multiple pharmacological actions, which translate into a wide‐spectrum therapeutic potential. Its major molecular targets are membrane adrenoceptors, ion channels, and reactive oxygen species. Carvedilol's favorable hemodynamic effects are due to the fact that the drug competitively blocks β1‐, β2‐
Gioia Turitto +2 more
openaire +2 more sources
2013
Carvedilol ((2RS)-1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol), a β1-, β2-, and α1-adrenoreceptor blocker drug with antioxidant and antiproliferative effects, is indicated for treatment of hypertension, stable angina pectoris, and congestive heart failure.
Jasmina Novakovic +2 more
openaire +3 more sources
Carvedilol ((2RS)-1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol), a β1-, β2-, and α1-adrenoreceptor blocker drug with antioxidant and antiproliferative effects, is indicated for treatment of hypertension, stable angina pectoris, and congestive heart failure.
Jasmina Novakovic +2 more
openaire +3 more sources